Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KYSA-1: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Next Previous
X
Search
Trial Profile

KYSA-1: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KYV-101 (Primary)
  • Indications Lupus nephritis
  • Focus Adverse reactions
  • Acronyms KYSA-1
  • Sponsors Kyverna Therapeutics

    • Most Recent Events

    • 14 Nov 2024 According to Kyverna Therapeutics media release, company will present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 Phase 1/2 study at a company symposium titled, "KYV-101 Anti-CD19 CAR T-Cell Therapy: The Future of Autoimmune Disease Treatment," to be held at ACR Convergence 5:45 pm ET on November 18, 2024.
    • 14 May 2024 According to Kyverna Therapeutics media release, treated 30 patients cumulatively as of May 14, 2024, including eight patients with myasthenia gravis, seven patients with lupus nephritis, and four patients with multiple sclerosis
    • 16 Apr 2024 The protocol has been amended to change in phase change to Phase 1/2 with addition of primary endpoint for efficacy of drug (Phase 2) with addition of treatment Arm with respective increase in patient population.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top